Autopsy report · NCT03422627
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Registered 3 months before it started.
- Ran for about 4 years 6 months before it stopped.
- 32 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Amgen
- Sponsor type
- Industry
- Conditions
- Chronic Graft Versus Host Disease cGVHD
- Interventions
- Efavaleukin Alfa
- Participants
- 32
- Sites
- 14
- Countries
- Belgium, France, Japan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.